Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Similar articles for PubMed (Select 24990616)

1.

Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma.

Brown R, Yang S, Weatherburn C, Gibson J, Ho PJ, Suen H, Hart D, Joshua D.

Leukemia. 2015 Feb;29(2):483-90. doi: 10.1038/leu.2014.204. Epub 2014 Jul 3.

PMID:
24990616
2.

Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML.

Marvin J, Swaminathan S, Kraker G, Chadburn A, Jacobberger J, Goolsby C.

Blood. 2011 Apr 14;117(15):e120-30. doi: 10.1182/blood-2010-10-316026. Epub 2011 Jan 13.

3.

Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma.

Denley SM, Jamieson NB, McCall P, Oien KA, Morton JP, Carter CR, Edwards J, McKay CJ.

J Gastrointest Surg. 2013 May;17(5):887-98. doi: 10.1007/s11605-013-2168-7. Epub 2013 Feb 23.

PMID:
23435739
4.

Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer.

Dobi E, Monnien F, Kim S, Ivanaj A, N'Guyen T, Demarchi M, Adotevi O, Thierry-Vuillemin A, Jary M, Kantelip B, Pivot X, Godet Y, Degano SV, Borg C.

Clin Colorectal Cancer. 2013 Mar;12(1):28-36. doi: 10.1016/j.clcc.2012.09.002. Epub 2012 Oct 17.

PMID:
23083634
5.

An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma.

Lin H, Kolosenko I, Björklund AC, Protsyuk D, Österborg A, Grandér D, Tamm KP.

Exp Cell Res. 2013 Mar 10;319(5):600-11. doi: 10.1016/j.yexcr.2012.12.006. Epub 2012 Dec 13.

PMID:
23246572
6.
7.

Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma.

Blix ES, Irish JM, Husebekk A, Delabie J, Forfang L, Tierens AM, Myklebust JH, Kolstad A.

BMC Cancer. 2012 Oct 16;12:478. doi: 10.1186/1471-2407-12-478.

8.

Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.

Haura EB, Zheng Z, Song L, Cantor A, Bepler G.

Clin Cancer Res. 2005 Dec 1;11(23):8288-94.

9.

Patients with acute pancreatitis complicated by organ failure show highly aberrant monocyte signaling profiles assessed by phospho-specific flow cytometry.

Oiva J, Mustonen H, Kylänpää ML, Kyhälä L, Alanärä T, Aittomäki S, Siitonen S, Kemppainen E, Puolakkainen P, Repo H.

Crit Care Med. 2010 Aug;38(8):1702-8. doi: 10.1097/CCM.0b013e3181e7161c.

PMID:
20512034
10.

High-resolution kinetics of cytokine signaling in human CD34/CD117-positive cells in unfractionated bone marrow.

Woost PG, Solchaga LA, Meyerson HJ, Shankey TV, Goolsby CL, Jacobberger JW.

Blood. 2011 Apr 14;117(15):e131-41. doi: 10.1182/blood-2010-10-316224. Epub 2011 Feb 17.

11.

Signal tranducers and activators of transcription: expression and function in anti-neutrophil cytoplasmic antibody-associated vasculitis.

Wilde B, Hoerning A, Kribben A, Witzke O, Dolff S.

Mol Med Rep. 2014 Jun;9(6):2316-20. doi: 10.3892/mmr.2014.2062. Epub 2014 Mar 20.

PMID:
24676862
12.

FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report.

Redell MS, Ruiz MJ, Gerbing RB, Alonzo TA, Lange BJ, Tweardy DJ, Meshinchi S; Children's Oncology Group.

Blood. 2013 Feb 14;121(7):1083-93. doi: 10.1182/blood-2012-04-421925. Epub 2012 Dec 14.

13.

Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP.

Gupta M, Maurer MJ, Wellik LE, Law ME, Han JJ, Ozsan N, Micallef IN, Dogan A, Witzig TE.

Blood. 2012 Nov 22;120(22):4400-6. doi: 10.1182/blood-2012-05-428466. Epub 2012 Sep 27.

14.

Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma.

Zöllinger A, Stühmer T, Chatterjee M, Gattenlöhner S, Haralambieva E, Müller-Hermelink HK, Andrulis M, Greiner A, Wesemeier C, Rath JC, Einsele H, Bargou RC.

Blood. 2008 Oct 15;112(8):3403-11. doi: 10.1182/blood-2007-11-119362. Epub 2008 Jul 17.

15.

Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation.

Ishikawa H, Tsuyama N, Abroun S, Liu S, Li FJ, Otsuyama K, Zheng X, Kawano MM.

Leuk Lymphoma. 2003 Sep;44(9):1477-81. Review.

PMID:
14565647
16.

In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway.

Chatterjee M, Hönemann D, Lentzsch S, Bommert K, Sers C, Herrmann P, Mathas S, Dörken B, Bargou RC.

Blood. 2002 Nov 1;100(9):3311-8.

17.

The expression and clinical significance of pSTAT3, VEGF and VEGF-C in pancreatic adenocarcinoma.

Huang C, Huang R, Chang W, Jiang T, Huang K, Cao J, Sun X, Qiu Z.

Neoplasma. 2012;59(1):52-61. doi: 10.4149/neo_2012_007.

PMID:
22082308
19.

STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells.

Hazan-Halevy I, Harris D, Liu Z, Liu J, Li P, Chen X, Shanker S, Ferrajoli A, Keating MJ, Estrov Z.

Blood. 2010 Apr 8;115(14):2852-63. doi: 10.1182/blood-2009-10-230060. Epub 2010 Feb 12.

20.

TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.

Ramakrishnan V, Kimlinger T, Haug J, Timm M, Wellik L, Halling T, Pardanani A, Tefferi A, Rajkumar SV, Kumar S.

Am J Hematol. 2010 Sep;85(9):675-86. doi: 10.1002/ajh.21785.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk